Inhibition of FGF‐FGFR and VEGF‐VEGFR signalling in cancer treatment,Cell Proliferation

当前位置： X-MOL 学术 › Cell Prolif. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Inhibition of FGF‐FGFR and VEGF‐VEGFR signalling in cancer treatment
Cell Proliferation ( IF 5.9 ) Pub Date : 2021-03-02 , DOI: 10.1111/cpr.13009
Guihong Liu ₁ , Tao Chen ₂ , Zhenyu Ding ₃ , Yang Wang ₁ , Yuquan Wei ₁ , Xiawei Wei ₁

Affiliation

The sites of targeted therapy are limited and need to be expanded. The FGF‐FGFR signalling plays pivotal roles in the oncogenic process, and FGF/FGFR inhibitors are a promising method to treat FGFR‐altered tumours. The VEGF‐VEGFR signalling is the most crucial pathway to induce angiogenesis, and inhibiting this cascade has already got success in treating tumours. While both their efficacy and antitumour spectrum are limited, combining FGF/FGFR inhibitors with VEGF/VEGFR inhibitors are an excellent way to optimize the curative effect and expand the antitumour range because their combination can target both tumour cells and the tumour microenvironment. In addition, biomarkers need to be developed to predict the efficacy, and combination with immune checkpoint inhibitors is a promising direction in the future. The article will discuss the FGF‐FGFR signalling pathway, the VEGF‐VEGFR signalling pathway, the rationale of combining these two signalling pathways and recent small‐molecule FGFR/VEGFR inhibitors based on clinical trials.

中文翻译：

FGF‐FGFR和VEGF‐VEGFR信号转导在癌症治疗中的抑制作用

靶向治疗的部位有限，需要扩大。FGF-FGFR信号在致癌过程中起着关键作用，而FGF / FGFR抑制剂是治疗FGFR改变的肿瘤的一种有前途的方法。VEGF-VEGFR信号传导是诱导血管生成的最关键途径，抑制这种级联反应已经在治疗肿瘤方面取得了成功。尽管它们的功效和抗肿瘤谱都受到限制，但将FGF / FGFR抑制剂与VEGF / VEGFR抑制剂组合使用是优化疗效和扩大抗肿瘤范围的绝佳方法，因为它们的组合可同时靶向肿瘤细胞和肿瘤微环境。另外，需要开发生物标志物以预测功效，并且与免疫检查点抑制剂的组合是未来的有希望的方向。

更新日期：2021-04-02

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11